Recent Finacing
Recent Raise
BiPar Sciences develops inhibitor-based cancer therapies that block tumor DNA repair, with a phase‑2 breast cancer lead, programs for ovarian and other malignancies, plus oral pancreatic and additional oncology candidates.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors